ArticlePloS one2025
Preliminary screening of new biomarkers for sepsis using bioinformatics and experimental validation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic and integrative based progression biomarker discovery in adult sepsis: toward clinical stratification and precision medicine.Annals of intensive care · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe morbidity and mortality of sepsis remain high, and so far specific diagnostic and therapeutic means are lacking.
objectiveTo screen novel biomarkers for sepsis.
methodsRaw sepsis data were downloaded from the Chinese National Genebank (CNGBdb) and screened for differentially expressed RNAs. Key genes with predictive value were identified through weighted correlation network analysis (WGCNA) and meta-analysis and survival analysis using multiple public databases. Core genes were analyzed for functional enrichment using Gene Set Enrichment Analysis(GSEA). The core genes were localized using single-cell sequencing. qPCR was used to validate the core genes.
resultsDifferential analysis yielded a total of 5125 mRNA. WGCNA identified 5 modules and screened 3 core genes (S100A11, QPCT, and IFITM2). The prognosis of sepsis patients was strongly linked to S100A11, QPCT, and IFITM2 based on meta-analysis and survival analysis(P < 0.05).GSEA analysis showed that S100A11, QPCT, and IFITM2 were significantly enriched in ribosome-related pathways. S100A11 and QPCT were widely distributed in all immune cells, and QPCT was mainly localized in the macrophage cell lineage. In the sepsis group, the qPCR results showed that S100A11, QPCT, and IFITM2 expression levels were significantly higher in the sepsis group(P < 0.05).
conclusionIn this study, S100A11, QPCT, and IFITM2 were screened as new potential biomarkers for sepsis. Validated by bioinformatics analysis and qPCR, these genes are closely associated with the prognosis of sepsis patients and have potential as diagnostic and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.